CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a
leading data-driven company focused on bringing real-world
evidence-driven from the point-of-care to the medical cannabis
community, today announced Prad Sekar, CEO of CB2 Insights will be
participating in a panel discussion and meeting with investors at
Piper Jaffray’s 31st Annual Healthcare Conference on December 3-5,
2019 in New York City. CB2 Insights will join nearly 300 public and
private companies in the biotechnology, specialty pharmaceutical,
drug discovery and medical technology space.
CB2 Insights is one of the leading global voices
in the move to mainstream medical cannabis into traditional
healthcare. The Company does so by leveraging its multi-state, US
clinical operations, its proprietary data collection technology and
contract research organization (CRO) services. Managing
full-service clinical operations and research services, CB2 has
amassed ongoing patient data of over 100,000 unique patients
annually who are seeking medical cannabis as an alternative or
complement to their traditional treatment regimen. CB2 Insights
assists Licensed Producers, Multi-State Operators (MSOs),
regulatory bodies and research agencies to assess the full safety
and efficacy of cannabinoid therapy.
“For years, medical cannabis has existed as a
fringe, alternative therapy, but we are now seeing a convergence of
traditional drug development processes with increasing positive
patient and government sentiment across the globe,” said Prad
Sekar, CEO, CB2 Insights. “Our work in the US, the UK, Colombia and
in Canada are all proving that traditional healthcare is ready to
take on cannabinoid-based medicines and our invitation to Piper
Jaffray’s Healthcare Conference further solidifies that
evolution.”
The panel discussion will be on Tuesday,
December 3 at 2:00 pm EST. As part of the panel,
“Understanding the Efficacy and Pharmacokinetics of
Cannabis,” Mr. Sekar will discuss how Real-World Data
(RWD) and Real-World Evidence (RWE) will be the key in accelerating
the shift of cannabis-based medicine into traditional healthcare.
With Real-World Data, we can move beyond traditional clinical
trials and start collecting insightful data at the
point-of-care.
About CB2 Insights
CB2 Insights (CSE:CBII) is a global leader in
clinical operations, technology & analytics solutions and
research and development services with a mission to mainstream
medical cannabis into traditional healthcare. Providing immediate
market access through its wholly-owned clinical network across 12
jurisdictions, proprietary data-driven technology solutions and
comprehensive contract research services designed for those in both
the medical cannabis and traditional life sciences industries, CB2
Insights is able to support its partners across the entire data and
research spectrum.
CB2’s Clinical Operations business unit
leverages extensive experience to develop clinical models with
standard operating procedures, advanced workflows, training and
ongoing management support. CB2 also owns and operates its own
speciality clinics including the brands Canna Care Docs and Relaxed
Clarity which assess over 100,000 patients annually seeking medical
cannabis treatment to provide immediate market access to US-based
product manufacturers for clinical trial and research programs.
The Company has built both electronic data
capture (EDC) and clinical data management software (CDMS) which
work to support its partners of any size to execute their data and
clinical strategies.
CB2 also offers comprehensive contract research
organization (CRO) services including full scale clinical trial
management, trial design, monitoring and other key research
functions used by licensed producers, multi-state operators and
traditional pharmaceutical companies entering the medical cannabis
space. For more information please visit www.cb2insights.com.
For additional information, please
contact:
Kim Nguyen – Director, Investor
Relations1.855.874.4999 ext. 212kim.nguyen@cb2insights.com
Forward Looking Statements
Statements in this news release that are
forward-looking statements are subject to various risks and
uncertainties concerning the specific factors disclosed here and
elsewhere in CB2’s filings with Canadian securities regulators.
When used in this news release, words such as "will, could, plan,
estimate, expect, intend, may, potential, believe, should," and
similar expressions, are forward-looking statements.
Forward-looking statements may include, without
limitation, statements regarding the opportunity to provide
services and software to the U.S. cannabis industry.
Although CB2 has attempted to identify important
factors that could cause actual results, performance or
achievements to differ materially from those contained in the
forward-looking statements, there can be other factors that cause
results, performance or achievements not to be as anticipated,
estimated or intended, including, but not limited to: dependence on
obtaining regulatory approvals; investing in target companies or
projects which have limited or no operating history and are subject
to inconsistent legislation and regulation; change in laws;
reliance on management; requirements for additional financing;
competition; hindering market growth and state adoption due to
inconsistent public opinion and perception of the medical-use and
recreational-use marijuana industry and; regulatory or political
change.
There can be no assurance that such information
will prove to be accurate or that management's expectations or
estimates of future developments, circumstances or results will
materialize. As a result of these risks and uncertainties, the
results or events predicted in these forward-looking statements may
differ materially from actual results or events.
Accordingly, readers should not place undue
reliance on forward-looking statements. The forward-looking
statements in this news release are made as of the date of this
release. CB2 disclaims any intention or obligation to update or
revise such information, except as required by applicable law, and
CB2 does not assume any liability for disclosure relating to any
other company mentioned herein.
No securities regulator or exchange has
reviewed, approved, disapproved, or accepts responsibility for the
content of this news release.
CB2 Insights (CSE:CBII)
Historical Stock Chart
From Mar 2024 to Apr 2024
CB2 Insights (CSE:CBII)
Historical Stock Chart
From Apr 2023 to Apr 2024